COVID-19 Therapeutics I: Clinical Evidence Studies for the Efficacy and Safety of ATR-002 in Patients with COVID-19 (MEK-I-COV)

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 16LW0001

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2023
  • Known Financial Commitments (USD)

    $13,915,182.87
  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principal Investigator

    N/A

  • Research Location

    Germany
  • Lead Research Institution

    ATRIVA Therapeutics GmbH
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract